Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...
Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...
Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...
Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...
Although the first GLP-1 drug was approved by the US Food and Drug Administration (FDA) in the early 2000s, it wasn't until a ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.
A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
The National Association of Attorneys General has submitted a letter to the U.S. Food and Drug Administration, signed by a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results